1Harris, AI. Handicapped and impaired in Great Britain. London: HMSO, 1971.Google Scholar

2Bamford, J, Sandercock, P, Dennis, M, Burn, J, Warlow, C. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project 1981–86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 1990; 53: 16–22.CrossRefGoogle Scholar

3Dennis, M, Bamford, J, Sandercock, P, Warlow, C. Prognosis of transient ischemic attacks in the Oxfordshire Community Stroke Project. Stroke 1990; 21: 848–53.CrossRefGoogle ScholarPubMed

4Hankey, GJ, Warlow, CP. Transient ischaemic attacks of the brain and eye. London: WB Saunders, 1994.Google Scholar

5Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy 1: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106.CrossRefGoogle Scholar

6Slattery, J, Warlow, CP, Shorrock, CJ, Langman, MJS. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin-analysis of gastrointestinal bleeding during the UK-TIA trial. Gut 1995; 37: 509–11.CrossRefGoogle ScholarPubMed

7Warlow, C. Ticlopidine, a new antithrombotic drug: but is it better than aspirin for longterm use? J Neurol Neurosurg Psychiatry 1990; 53: 185–87.CrossRefGoogle ScholarPubMed

8 Anon. Major ongoing stroke trials. Stroke 1995; 26: 1978–82.Google Scholar

9Meade, TW, Wilkes, HC, Stirling, Y, Brennan, PJ, Kelleher, C, Browne, W. Randomized controlled trial of low dose warfarin in the primary prevention of ischaemic heart disease in men at high risk: design and pilot study. Eur Heart J 1988; 9: 836–43.CrossRefGoogle ScholarPubMed

10Jonas, S. Anticoagulant therapy in cerebrovascular disease: review and meta-analysis. Stroke 1988; 19: 1043–48.CrossRefGoogle ScholarPubMed

11ASPECT Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994; 343: 499–503.Google Scholar

12Smith, P, Arnesen, H, Holme, I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147–52.CrossRefGoogle ScholarPubMed

13Cairns, JA. Oral anticoagulants or aspirin after myocardial infarction? Lancet 1994; 343: 497–98.CrossRefGoogle ScholarPubMed

14Bogousslavsky, J, Hachinski, VC, Boughner, DR, Fox, AJ, Viñuela, F, Barnett, HJM. Cardiac and arterial lesions in carotid transient ischemie attacks. Arch Neurol 1986; 43: 223–28.CrossRefGoogle Scholar

15Sandercock, PA, Warlow, CP, Jones, LN, Starkey, IR. Predisposing factors for cerebral infarction: the Oxfordshire community stroke project. BMJ 1989; 298: 75–80.CrossRefGoogle ScholarPubMed

16Wolf, PA, Dawber, TR, Thomas, HE, Kannel, WB. Epidemiological assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978; 28: 973–77.CrossRefGoogle ScholarPubMed

17Flegel, KM, Shipley, MJ, Rose, G. Risk of stroke in non-rheumatic atrial fibrillation. Lancet 1987; i: 526–29.CrossRefGoogle Scholar

18Rose, G, Baxter, PJ, Reid, DD, McCartney, P. Prevalence and prognosis of electrocardiographic findings in middle-aged men. Br Heart J 1978; 40: 636–43.CrossRefGoogle ScholarPubMed

19Kannel, WB, Abbott, RD, Savage, DD, McNamara, PM. Epidemiological features of chronic atrial fibrillation. N Engl J Med 1982; 306: 1018–22.CrossRefGoogle ScholarPubMed

20Ostrander, LD, Brandt, RL, Kjelsberg, MO, Epstein, FH. Electrocardiography findings among the adult population of a total natural community, Tecumseh, Michigan. Circulation 1965; 31: 888–98.CrossRefGoogle ScholarPubMed

21Petersen, P, Boysen, G, Godtfredsen, J, Andersen, ED, Andersen, B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1: 175–79.CrossRefGoogle ScholarPubMed

22The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505–11.CrossRefGoogle Scholar

23Connolly, SJ, Laupacis, A, Gent, M, Roberts, RS, Cairns, JA, Joyner, C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18: 349–55.CrossRefGoogle ScholarPubMed

24Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84: 527–39.CrossRefGoogle Scholar

25Ezekowitz, MD, Bridgers, SL, James, KE et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327: 1406–12.CrossRefGoogle ScholarPubMed

26Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687–91.Google Scholar

27Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994; 154: 1449–57.CrossRefGoogle Scholar

28Gustafsson, C, Asplund, K, Britton, M, Norrving, B, Olsson, B, Marké, L. Cost-effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ 1992; 305: 1457–60.CrossRefGoogle ScholarPubMed

29Sweeney, KG, Pereira, Gray DJ, Steele, RJF, Evans, PH. Commentary: caution needed in introducing warfarin treatment. BMJ 1995; 311: 560–61.CrossRefGoogle ScholarPubMed

30Sudlow, CM, Rodgers, H, Kenny, RA, Thomson, RG. Service provision and use of anticoagulants in atrial fibrillation. BMJ 1995; 311: 558–60.CrossRefGoogle ScholarPubMed

31EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255–62.CrossRefGoogle Scholar

32Koudstaal, P. Secondary prevention following stroke or transient ischaemic attack in patients with nonrheumatic atrial fibrillation: antiplatelet therapy versus control. In: Warlow, C, Van Gijn, J, Sandercock, P eds. Stroke module of the Cochrane database of systematic reviews. London: BMJ Publishing Group, 1995.Google Scholar

33Koudstaal, P. Secondary prevention following stroke or transient ischaemic attack in patients with nonrheumatic atrial fibrillation: anticoagulant therapy versus control. In: Warlow, C, Van Gijn, J, Sandercock, P eds. Stroke module of the Cochrane database of systematic reviews. London: BMJ Publishing Group, 1995.Google Scholar

34Koudstaal, P. Secondary prevention following stroke or transient ischaemic attack in patients with nonrheumatic atrial fibrillation: anticoagulant versus antiplatelet therapy. In: Warlow, C, Van Gijn, J, Sandercock, P eds. Stroke module of the Cochrane database of systematic reviews. London: BMJ Publishing Group, 1995.Google Scholar

35Sandercock, P, Bamford, J, Dennis, M et al. Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire community stroke project). BMJ 1992; 305: 1460–65.CrossRefGoogle ScholarPubMed

36The UK-TIA Study Group. Intracranial tumours that mimic transient cerebral ischaemia: lessons from a large multicentre trial. J Neurol Neurosurg Psychiatry 1993; 56: 563–66.CrossRefGoogle Scholar

37Rimdusid, P, Wardlaw, J, Lindley, RI, Sandercock, P. Haemorrhagic infarction in acute ischaemic stroke patients: International Stroke Trial Pilot Study [Abstract]. Cerebrovasc Dis 1995; 5: 264.Google Scholar

38International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (1ST), baseline data, and outcome in 984 randomised patients in the pilot study. J Neurol Neurosurg Psychiatry 1996; 60: 371–76.CrossRefGoogle Scholar